Medtox Scientific — Investor Presentation (June 2011)
7 slides from Medtox Scientific's investor presentation, Jun 15, 2011
Slide 1: 2011 Investor Sheet
2011 Investor Sheet MEDIOX EE las ony Profitable growth Builel market share in large markets (relative to our size) by oflering high quality products and services, priced competitively and supported by value added services > Leverage existing infrastructure and technical expertise to improve operati
Slide 2: Drugs of Abuse Testing
72011 Investor Sheet MEDI x ‘NASDAQ Symbok: MTOX Drugs of Abuse Testing, > Estimated $750 million market > 2010 revenues © $39.6 million, up 9.9% fiom 2009 ‘© Revenues from existing clients declined but stabilized throughout the year ©. Growth driver revenues from new clients Economie recovery provi
Slide 3: Clinical and Other Laboratory Services
72011 Investor Sheet MEDI x ‘NASDAQ Symbok: MTOX Clinical and Other Laboratory Services > Estimated $50 billion market © Clinical toxicology © Clinical testing for cocupational health clinies ‘© Heavy metal, trace element and solvent analysis ‘© Testing. prescription/pein management- ToxASSURE® ‘Sig
Slide 4: Clinical Trial Services
72011 Investor Sheet MEDI x ‘NASDAQ Symbok: MTOX Clinical Trial Services > Estimated over SI billion dollar market > ‘Services provided ‘© Central laboratory services Assay development Bio-analytical Bio-equivalence (© Pharmacokinetic testing > 2010 Revenue $7.5 million > Project oriented and subjec
Slide 5: Diagnostic Products
2011 Investor Sheet [NASDAQ Symbol: MTOX Diagnostic Products -Point-ofcoletion testing products for drugs-o-abuse testing > Estimated $400 - $500 million market > 2010 revenues $20.1 million > QL 2011 revenues up 20.3% Markets >» Workplace drugs-of-abuse testing © Economic recovery provides opportun
Slide 6: Consolidated Statements of Income
72011 Investor Sheet MEDTOX’ A el MEDTOX SCIENTIFIC, INC. ‘CONSOLIDATED STATEMENTS OF INCOME {dn thousands, except share and per share data) (nauaited) Mar 31, Mar 31, zovi-ato_ —_2010-arD. vwsoos svar REVENUES Laboratory Services: Drugs-oFabuse testing services a sow 2% Cinial& ether laboratory ser
Slide 7: Summary
72011 Investor Sheet MEDIOX: Se Summary Solid positions in large markets relative to our size Increased revenue diversification Growth drivers in non-empl fed areas vyvvy P ‘and positive cash flow Each indicator represents an active client location for MEDTOX Lab services
Medtox Scientific — Investor Presentation (June 2011) on 6ix